Sanofi compounds to be featured in 178 abstracts at American Society of Hematology Annual Meeting

Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that new research spanning the company’s marketed and investigational hematology products, including its late-stage selective JAK2 inhibitor, will be featured in 178 abstracts to be presented at the 2012 Annual Meeting of the American Society of Hematology in Atlanta, GA., December 8-11, 2012.

“We have a strong commitment to developing treatment solutions for patients with difficult-to-treat blood cancers where there remains unmet medical need,” said Debasish Roychowdhury, M.D., Senior Vice President and Head, Sanofi Oncology. “At this year’s ASH, we unveil for the hematology community our selective JAK2 inhibitor, which we are investigating to fill existing treatment gaps in myelofibrosis. We look forward to the results of our Phase III trial in 2013.”

Abstracts to be presented at the meeting cover the latest research on Sanofi Oncology’s marketed hematology products Clolar®/Evoltra®, Elitek®, Mozobil® and Thymoglobuline® as well as the novel, investigational selective JAK2 inhibitor (SAR302503). Sanofi Oncology’s JAK2 inhibitor is in clinical development for the treatment of the three main types of myeloproliferative neoplasms: primary myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET).

Key abstracts to be presented at ASH include:

• A Phase II randomized dose-ranging study of the JAK2 selective inhibitor SAR302503 in patients with intermediate-2 or high-risk primary myelofibrosis, post–polycythemia vera MF or post-essential thrombocythemia MF
  * Presenter: Moshe Talpaz, M.D., University of Michigan, USA
  * Poster #2837, Sunday December 9, 6:00pm – 8:00pm, Hall B1-B2, Building B
• Analysis of the impact and burden of illness of polycythemia vera and essential thrombocythemia in the US
  * Presenter: Jyotsna Mehta, Sanofi, Cambridge, USA
  * Poster #2071; Saturday, December 8, 5:30pm – 7:30 pm, Hall B1-B2, Building B
• Epidemiology of myelofibrosis, polycythemia vera and essential thrombocythemia in the European Union
  * Odile Moulard, Sanofi, Chilly Mazarin, France
  * Poster #1744, Saturday, December 8, 5:30 pm – 7:30 pm, Hall B1-B2, Building B
• Epidemiology of myeloproliferative disorders in US – a real world analysis
  * Presenter: Ruben Mesa, M.D., Mayo Clinic Arizona, USA
  * Poster #2834; Sunday, December 9, 6:00pm – 8:00 pm, Hall B1-B2, Building B
• Analysis of the impact and burden of illness of myelofibrosis in the US
  * Presenter: Hongwei Wang, Sanofi, Bridgewater, USA
  * Oral presentation #972; Tuesday, December 11, C211-C213, Building C

About the Sanofi JAK2 Inhibitor

JAK2 is a key enzyme for blood cell development. Mutations in JAK2 can lead to dysregulated JAK2 signaling and are thought to be a cause of MF. Patients with wild type JAK2 have also been shown to have persistent, dysregulated activation of the JAK2 signaling pathway, which may be caused by mutations in other proteins believed to drive the development of the disease. In early clinical studies, the Sanofi JAK2 inhibitor has shown activity in MF patients with both wild type and mutated (JAK2V617F) JAK2.

About Clolar®/Evoltra®

Approved in 49 countries, Clolar/Evoltra is for the treatment of pediatric patients with relapsed or refractory acute lymphoblastic leukemia (ALL) after at least two prior treatment options. Randomized trials demonstrating increased survival or other clinical benefit have not been conducted. Clolar/Evoltra was the first chemotherapy in more than a decade approved specifically for children with ALL.

About Mozobil®

Approved in 42 countries, Mozobil rapidly and effectively increases the number of hematopoietic stem cells in the blood to prepare non-Hodgkin’s lymphoma and multiple myeloma patients for an autologous hematopoietic stem cell transplant. Mozobil is used with another medication (G-CSF) to release hematopoietic stem cells from the bone marrow into the bloodstream by disrupting a bond that normally keeps stem cells anchored to the bone marrow.

About Thymoglobuline®

For the past 25 years outside of the US, and currently registered in 60 countries around the world for a variety of indications, Thymoglobuline has been an integral part of the immunosuppressive regimen for patients undergoing solid organ and allogeneic stem cell transplantation as well as a standard of care for patients with aplastic anemia who cannot undergo a stem cell transplantation. Thymoglobuline remains an appropriate first-line immunosuppressive therapy in the treatment of aplastic anemia based on its positive benefit/risk profile in those countries where no horse ATG is available.